Last Chance to Register For The ATN Innovation Summit!
Secure your spot and join 750+ industry executives on June 16 & 17 in NYC.
GLP-1s are more accessible than ever, with everyone from gyms and telehealth companies offering prescriptions to weight loss medication. Support ranges the gamut: some online platforms act as an insurance concierge and offer regular virtual check-ins with a health professional, while others provide seamless access through a self-led program.
The psychology-based platform’s new Microdose GLP-1Rx Program is affordable and is designed to be easy on your body.
New data from Noom suggests that people who put more effort into eating healthy and working out see the best results from weight-loss drugs.
GLP-1s deliver dramatic weight loss, but a new study reveals what happens when treatment stops and why weight often comes back fast.
Big-box gyms and health clubs are acquiring new members (especially Gen Z) at a rapid clip, but they’re also struggling to keep them around.
Noom’s microdose GLP-1 program targets early metabolic risk and longevity, offering weight-loss drugs to adults with a BMI of 21 or higher.
New Gallup data shows GLP-1 use has doubled nationwide as telehealth startups and investors are reshaping the weight-loss market.
Noom teams up with Haut.AI to launch Future Me, a tool that lets users preview how lifestyle choices could visibly shape aging and wellness.
From AI wearables to GLP-1s and social fitness, UBS’s event spotlighted the innovations driving the $2 trillion wellness market.
Rebel Wilson joins Noom as chief wellness ambassador, backing its new free tier that gamifies healthy habits and spotlights microdose GLP-1s.
Sign Up to Our Newsletter
